Skip to main content
Sansure Biotech Inc. logo

Sansure Biotech Inc. — Investor Relations & Filings

Ticker · 688289 ISIN · CNE1000043J1 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 873 across all filing types
Latest filing 2021-03-29 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688289

About Sansure Biotech Inc.

https://www.sansureglobal.com/

Sansure Biotech Inc. specializes in the development and manufacture of molecular diagnostic products and genetic testing solutions. The company utilizes proprietary technologies, such as the "One-tube" fast extraction method and advanced magnetic bead technology, to provide high-sensitivity PCR diagnostic kits. Its product portfolio covers a wide range of clinical applications, including infectious disease screening for hepatitis, respiratory infections, and sexually transmitted infections, as well as oncology and maternal health. Sansure also provides integrated laboratory automation systems, including nucleic acid extractors and real-time PCR instruments, designed to streamline clinical workflows and improve diagnostic efficiency for healthcare providers and research institutions globally.

Recent filings

Filing Released Lang Actions
圣湘生物科技股份有限公司独立董事关于第一届董事会2021年第二次会议相关事宜的事前认可意见
Audit Report / Information Classification · 90% confidence The document is a statement from an independent director regarding the pre-approval of the reappointment of the 2021 audit firm for the company. It references the audit firm and the audit engagement for the year 2021 but does not contain any actual audit report or financial data. The document is short (514 characters) and serves as an opinion or approval related to audit matters, not the audit report itself. Therefore, it is best classified as an Audit Report / Information (AR) since it relates to audit matters but is not a full annual report or financial statement. FY 2021
2021-03-29 Chinese
中审众环会计师事务所（特殊普通合伙）关于圣湘生物科技股份有限公司非经营性资金占用及其他关联资金往来情况汇总表的专项审核报告
Audit Report / Information Classification · 95% confidence The document is a specialized audit report titled "专项审核报告" related to the non-operating funds occupation and other related party fund transactions of 圣湘生物科技股份有限公司 for the year ended December 31, 2020. It is issued by a certified public accounting firm (Mazars) and includes detailed audit procedures and opinions on a specific financial summary table. The document contains audit findings and is not a full annual report but a standalone audit report focusing on a particular aspect of the company's financials. It is not a general regulatory filing, certification, or announcement of a report but an actual audit report with substantive content. Therefore, the appropriate classification is Audit Report / Information (AR).
2021-03-29 Chinese
圣湘生物科技股份有限公司独立董事对公司对外担保情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a special statement by independent directors regarding the company's external guarantees for the year 2020. It references regulatory notices from the China Securities Regulatory Commission and confirms no external guarantees or violations during the reporting period. The document is a standalone audit-related statement focusing on compliance and assurance about a specific financial aspect (external guarantees). It does not contain full financial statements or comprehensive annual report content, nor is it a brief announcement or a certification letter. Therefore, it fits best under Audit Report / Information (AR). The document length is short but contains substantive audit-related content, not merely an announcement or certification. FY 2020
2021-03-29 Chinese
圣湘生物科技股份有限公司审计委员会2020年度履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled '审计委员会 2020 年度履职情况报告' which translates to 'Audit Committee 2020 Annual Performance Report'. It details the activities and responsibilities performed by the Audit Committee during the year 2020, including oversight of audit reports, internal controls, and external auditor evaluations. The content focuses on the committee's supervisory and evaluative functions rather than presenting full financial statements or comprehensive annual financial data. The document length is relatively short (1324 characters), and it is a report on the committee's duties rather than a full audit report or annual report. Therefore, it fits best under the category of Audit Report / Information (AR), which includes standalone audit reports and related information, excluding full annual reports. FY 2020
2021-03-29 Chinese
圣湘生物科技股份有限公司第一届董事会2021年第二次会议决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at a board meeting of 圣湘生物科技股份有限公司 (Shengxiang Bio-tech Co., Ltd.) held on March 26, 2021. It includes approval of the 2020 Board Work Report, 2020 Profit Distribution Plan, 2020 Annual Report and Summary, reappointment of the audit firm for 2021, remuneration plans for directors and senior management, a special report on the use of raised funds, audit committee report, internal control evaluation, and plans for the 2020 Annual General Meeting. The document is not the annual report itself but a board meeting resolution announcement that includes approval of various reports and proposals to be submitted to the shareholders' meeting. It also includes a proposal for a bank credit line. The document is a formal board meeting resolution announcement, which fits best under Board/Management Information (MANG) as it concerns board decisions and management matters. The document length is under 5,000 characters, but it contains substantive content of board resolutions, not just a brief announcement or a certification. Therefore, the classification is MANG with high confidence.
2021-03-29 Chinese
圣湘生物科技股份有限公司独立董事关于第一届董事会2021年第二次会议相关事宜的独立意见
Board/Management Information Classification · 95% confidence The document is an independent director's opinion on several proposals and reports related to the company's 2020 fiscal year and 2021 plans, including profit distribution, auditor reappointment, director and senior management remuneration, and a special report on the use of raised funds. It references compliance with laws and regulations and the review of these matters by the board. The document is not the full annual report or audit report itself but an opinion on these matters, typically presented as part of board or management information disclosures. It does not contain full financial statements or detailed financial analysis, nor is it a short announcement of a report publication. The content aligns best with Board/Management Information (MANG) as it concerns board meeting matters and management proposals.
2021-03-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.